Research Technician
Suzanne van Veen
Research
Senior research technician, experienced in transcriptomic and proteomic biomarker studies. My work comprises wet-lab experiments and bioinformatic data analysis, focussed on host immune responses in clinical trial settings. I have contributed to projects on vaccine-induced immunity to Ebola virus and treatment responses in patients with tuberculosis across different subpopulations. In addition, I do in vitro work on host-directed therapeutic approaches against Mycobacterium tuberculosis. Finally, I am responsible for our PCR labs and am involved in the LUCID-GRP and -Green teams.
Curriculum Vitae
In 2016, I obtained my BSc in Biology and Medical Laboratory Education at Hogeschool Leiden and started as a technician at the Viroscience Department of the Erasmus MC. In 2017, I started at the LUMC in the group of Tom Ottenhoff (department of Infectious Diseases). In 2025, I obtained my MSc in Molecular, Cellular and Organismal Biology at Leiden University. Currently I work in the group of Simone Joosten on in vitro assessment of immunotherapeutics for tuberculosis
Publications
-
Transcriptomic signatures induced by the Ebola virus vaccine rVSVΔG-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: A molecular biomarker study.
Vianello, E., Gonzalez-Dias, P., van Veen, S., Engele, C. G., Quinten, E., Monath, T. P., Medaglini, D., Agnandji, S. T., Ahmed, R., Anderson, J., Auderset, F., Bejon, P., Borgianni, L., Brosnahan, J., Ciabattini, A., … Siegrist, C.-A.
The Lancet Microbe, 3(2), e113–e123. https://doi.org/10.1016/S2666-5247(21)00235-4
-
Longitudinal soluble marker profiles reveal strong association between cytokine storms resulting from macrophage activation and disease severity in COVID-19 disease.
van Meijgaarden, K.E., van Veen, S., Tsonaka, R. et al.
Sci Rep 14, 12882 (2024). https://doi.org/10.1038/s41598-024-63586-8
-
Transcriptional profiles predict treatment outcome in patients with tuberculosis and diabetes at diagnosis and at two weeks after initiation of anti-tuberculosis treatment.
van Doorn CLR, Eckold C, Ronacher K, Ruslami R, van Veen S, Lee JS, Kumar V, Kerry-Barnard S, Malherbe ST, Kleynhans L, Stanley K, Hill PC, Joosten SA, van Crevel R, Wijmenga C, Critchley JA, Walzl G, Alisjahbana B, et al.
EBioMedicine. 2022 Aug;82:104173. doi: 10.1016/j.ebiom.2022.104173. Epub 2022 Jul 15. PMID: 35841871; PMCID: PMC9297076.
